Rapport Therapeutics has derived what it believes is 'unprecedented' early efficacy for its precision neuroscience treatment in focal onset seizures - its confidence comes from a unique trial design

blonca9
21 minutes ago
1 min read

CEO Abe Ceesay describes Rapport's precision neuroscience approach of targeting the AMPA receptor specifically through TARPγ8, and explains why the company took the extra step of tracking an electrographic biomarker in its phase 2a study in addition to seizure frequency. Plus, next steps and additional indications.

Recent Posts

See All

ASH 2025: Kelonia Therapeutics presented convincing late-breaking data at ASH today from its initial patients in multiple myeloma suggesting that in vivo CAR-T is on track to be a next innovation

$ASH 2025: MaaT Pharma's microbiome based treatment for refractory GVHD is in front of EMA right now for a possible 2026 approval - the pivotal data was presented in an oral at ASH this week$

ASH 2025: MaaT Pharma's microbiome based treatment for refractory GVHD is in front of EMA right now for a possible 2026 approval - the pivotal data was presented in an oral at ASH this week

ASH 2025: Ascentage Pharma Chairman & CEO Dajun Yang shares an update on the company's Bcl-2, lisaftoclax, which was recently approved in China and is in multiple global registration studies

Rapport Therapeutics has derived what it believes is 'unprecedented' early efficacy for its precision neuroscience treatment in focal onset seizures - its confidence comes from a unique trial design

Recent Posts

Join the BiotechTV mailing list

Follow BiotechTV

Sponsors

Sponsor Spotlight